{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:05:05Z","timestamp":1789707905204,"version":"4.0.1"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Paediatric Respiratory Reviews"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.prrv.2024.07.004","type":"journal-article","created":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T15:58:26Z","timestamp":1726847906000},"page":"70-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Impact of highly effective modulator therapy on gastrointestinal symptoms and features in people with cystic fibrosis"],"prefix":"10.1016","volume":"54","author":[{"given":"Martina","family":"Cecchetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Scarallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Lionetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chee Y.","family":"Ooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1106-4424","authenticated-orcid":false,"given":"Vito","family":"Terlizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prrv.2024.07.004_b0005","article-title":"Update on advances in cystic fibrosis towards a cure and implications for primary care clinicians","volume":"54","author":"Terlizzi","year":"2024","journal-title":"Curr Probl Pediatr Adolesc Health Care"},{"key":"10.1016\/j.prrv.2024.07.004_b0010","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev.genom.6.080604.162254","article-title":"Modifier genetics: cystic fibrosis","volume":"6","author":"Cutting","year":"2005","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"10.1016\/j.prrv.2024.07.004_b0015","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/thorax-2023-220100","article-title":"A refresh of the top 10 research priorities in cystic fibrosis","volume":"78","author":"Rowbotham","year":"2023","journal-title":"Thorax"},{"key":"10.1016\/j.prrv.2024.07.004_b0020","first-page":"9","article-title":"Changing paradigms in the treatment of gastrointestinal complications of cystic fibrosis in the era of cystic fibrosis transmembrane conductance regulator modulators","volume":"42","author":"Konrad","year":"2022","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.prrv.2024.07.004_b0025","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.914790","article-title":"The exocrine pancreas in cystic fibrosis in the era of CFTR modulation: a mini review","volume":"10","author":"McKay","year":"2022","journal-title":"Front Pediatr"},{"key":"10.1016\/j.prrv.2024.07.004_b0030","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/path.4634","article-title":"Pancreatic pathophysiology in cystic fibrosis","volume":"238","author":"Gibson-Corley","year":"2016","journal-title":"J Pathol"},{"key":"10.1016\/j.prrv.2024.07.004_b0035","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1275470","article-title":"Efficacy and safety profile of elexacaftor-tezacaftor-ivacaftor triple therapy on cystic fibrosis: a systematic review and single arm meta-analysis","volume":"14","author":"Xu","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.prrv.2024.07.004_b0040","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1007\/s00431-021-04168-y","article-title":"A new era for people with cystic fibrosis","volume":"180","author":"Bierlaagh","year":"2021","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.prrv.2024.07.004_b0045","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","article-title":"CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine","volume":"10","author":"Lopes-Pacheco","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.prrv.2024.07.004_b0050","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.prrv.2024.07.004_b0055","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0140-6736(23)01609-4","article-title":"CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis","volume":"402","author":"Taylor-Cousar","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.prrv.2024.07.004_b0060","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prrv.2024.07.004_b0065","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jcf.2022.10.006","article-title":"GALAXY Study Group. Multicenter prospective study showing a high gastrointestinal symptom burden in cystic fibrosis","volume":"22","author":"Moshiree","year":"2023","journal-title":"J Cyst Fibros."},{"key":"10.1016\/j.prrv.2024.07.004_b0070","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1136\/gut.52.8.1159","article-title":"Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas","volume":"52","author":"Ahmed","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.prrv.2024.07.004_b0075","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/MPG.0000000000001868","article-title":"CFTR protein function modulation therapy is finally targeting cystic fibrosis-related gastrointestinal disease","volume":"66","author":"Bodewes","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.prrv.2024.07.004_b0080","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1046\/j.1469-1809.2003.00028.x","article-title":"The phenotypic consequences of CFTR mutations","volume":"67","author":"Rowntree","year":"2003","journal-title":"Ann Hum Genet"},{"key":"10.1016\/j.prrv.2024.07.004_b0085","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(15)00545-7","article-title":"KIWI Study Group. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study","volume":"4","author":"Davies","year":"2016","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.prrv.2024.07.004_b0090","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/s41395-018-0123-7","article-title":"Ivacaftor CFTR potentiator therapy is efficient for pancreatic manifestations in cystic fibrosis","volume":"113","author":"Kounis","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.prrv.2024.07.004_b0095","doi-asserted-by":"crossref","first-page":"E16","DOI":"10.1002\/ppul.24353","article-title":"Time for a gut check: pancreatic sufficiency resulting from CFTR modulator use","volume":"54","author":"Megalaa","year":"2019","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.prrv.2024.07.004_b0100","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jcf.2019.03.009","article-title":"KLIMB study group. An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2\u20135 years (KLIMB)","volume":"18","author":"Rosenfeld","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.prrv.2024.07.004_b0105","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","article-title":"Phase 3 open-label clinical trial of elexacaftor\/tezacaftor\/ivacaftor in children aged 2\u20135 years with cystic fibrosis and at least One F508del allele","volume":"208","author":"Goralski","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prrv.2024.07.004_b0110","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1164\/rccm.202204-0734OC","article-title":"A phase 3, open-label study of lumacaftor\/ivacaftor in children 1 to less than 2 years of age with cystic fibrosis homozygous for F508del-CFTR","volume":"206","author":"Rayment","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prrv.2024.07.004_b0115","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1164\/rccm.202008-3177OC","article-title":"Ivacaftor in infants aged 4 to <12 months with cystic fibrosis and a gating mutation. results of a two-part phase 3 clinical trial","volume":"203","author":"Davies","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"485","key":"10.1016\/j.prrv.2024.07.004_b0120","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau7531","article-title":"In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis","volume":"11","author":"Sun","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.prrv.2024.07.004_b0125","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jcf.2021.03.018","article-title":"Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy","volume":"20","author":"Fortner","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.prrv.2024.07.004_b0130","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/MPG.0000000000001788","article-title":"Reduction of recurrence risk of pancreatitis in cystic fibrosis with ivacaftor: case series","volume":"66","author":"Carrion","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.prrv.2024.07.004_b0135","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jcf.2021.09.010","article-title":"CFTR modulators increase risk of acute pancreatitis in pancreatic insufficient patients with cystic fibrosis","volume":"21","author":"Gould","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.prrv.2024.07.004_b0140","doi-asserted-by":"crossref","first-page":"E16","DOI":"10.1002\/ppul.24353","article-title":"Time for a gut check: pancreatic sufficiency resulting from CFTR modulator use","volume":"54","author":"Megalaa","year":"2019","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.prrv.2024.07.004_b0145","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/gim.2015.79","article-title":"Prevalence of meconium ileus marks the severity of mutations of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene","volume":"18","author":"Dupuis","year":"2016","journal-title":"Genet Med"},{"key":"10.1016\/j.prrv.2024.07.004_b0150","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","article-title":"Cystic fibrosis","volume":"373","author":"O'Sullivan","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.prrv.2024.07.004_b0155","doi-asserted-by":"crossref","first-page":"24857","DOI":"10.1038\/srep24857","article-title":"Disrupted progression of the intestinal microbiota with age in children with cystic fibrosis","volume":"6","author":"Nielsen","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.prrv.2024.07.004_b0160","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/cid\/cit715","article-title":"Escherichia coli dysbiosis correlates with gastrointestinal dysfunction in children with cystic fibrosis","volume":"58","author":"Hoffman","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.prrv.2024.07.004_b0165","article-title":"Probiotics for people with cystic fibrosis","volume":"1","author":"Coffey","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.prrv.2024.07.004_b0170","doi-asserted-by":"crossref","first-page":"17834","DOI":"10.1038\/s41598-018-36364-6","article-title":"Impact of CFTR modulation with ivacaftor on gut microbiota and intestinal inflammation","volume":"8","author":"Ooi","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.prrv.2024.07.004_b0175","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01175-23","article-title":"Tezacaftor\/Ivacaftor therapy has negligible effects on the cystic fibrosis gut microbiome","volume":"11","author":"Marsh","year":"2023","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.prrv.2024.07.004_b0180","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.01935-23","article-title":"Longitudinal profiling of the intestinal microbiome in children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor","volume":"15","author":"Reasoner","year":"2024","journal-title":"MBio"},{"key":"10.1016\/j.prrv.2024.07.004_b0185","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.cgh.2007.02.033","article-title":"Determinants of gastroesophageal reflux disease in adults with a history of childhood gastroesophageal reflux disease","volume":"5","author":"El-Serag","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.prrv.2024.07.004_b0190","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/014107689809100103","article-title":"Prevalence and mechanisms of gastro-oesophageal reflux in adult cystic fibrosis patients","volume":"91","author":"Ledson","year":"1998","journal-title":"J R Soc Med"},{"key":"10.1016\/j.prrv.2024.07.004_b0195","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/0929-693X(96)81243-7","article-title":"Frequency of gastroesophageal reflux in infants and in young children with cystic fibrosis","volume":"2","author":"Vic","year":"1995","journal-title":"Arch Pediatr"},{"key":"10.1016\/j.prrv.2024.07.004_b0200","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1177\/084653718803900204","article-title":"The association of cystic fibrosis, gastroesophageal reflux, and reduced pulmonary function","volume":"39","author":"Stringer","year":"1988","journal-title":"Can Assoc Radiol J"},{"key":"10.1016\/j.prrv.2024.07.004_b0205","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jcf.2020.06.004","article-title":"Postprandial changes in gastrointestinal function and transit in cystic fibrosis assessed by magnetic resonance imaging","volume":"20","author":"Ng","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.prrv.2024.07.004_b0210","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jcf.2021.12.007","article-title":"Magnetic resonance imaging of the gastrointestinal tract shows reduced small bowel motility and altered chyme in cystic fibrosis compared to controls","volume":"21","author":"Dellschaft","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.prrv.2024.07.004_b0215","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1001\/jamapediatrics.2023.2900","article-title":"Proton pump inhibitor use and risk of serious infections in young children","volume":"177","author":"Lassalle","year":"2023","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.prrv.2024.07.004_b0220","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/jamapediatrics.2020.0007","article-title":"Association between proton pump inhibitor use and risk of fracture in children","volume":"174","author":"Wang","year":"2020","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.prrv.2024.07.004_b0225","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jcf.2022.06.003","article-title":"Elexacaftor-tezacaftor-ivacaftor improve gastro-oesophageal reflux and sinonasal symptoms in advanced cystic fibrosis","volume":"21","author":"Shakir","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.prrv.2024.07.004_b0230","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1002\/ppul.26694","article-title":"Gastroesophageal reflux burden in youth with CF treated with elexacaftor-tezacaftor-ivacaftor","volume":"58","author":"Bass","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.prrv.2024.07.004_b0235","article-title":"RECOVER Study Group. Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged \u226512 years - The RECOVER study","author":"Mainz","year":"2023","journal-title":"J Cyst Fibros."},{"key":"10.1016\/j.prrv.2024.07.004_b0240","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jcf.2016.07.004","article-title":"Ivacaftor and symptoms of extra-oesophageal reflux in patients with cystic fibrosis and G551D mutation","volume":"16","author":"Zeybel","year":"2017","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.prrv.2024.07.004_b0245","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1038\/ctg.2017.10","article-title":"Impact of CFTR modulation on intestinal pH, motility, and clinical outcomes in patients with cystic fibrosis and the G551D mutation","volume":"8","author":"Gelfond","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.prrv.2024.07.004_b0250","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3310\/nihropenres.13384.1","article-title":"A grumbling concern: an international survey of gastrointestinal symptoms in cystic fibrosis in the modulator era","volume":"3","author":"Calthorpe","year":"2023","journal-title":"NIHR Open Res"},{"key":"10.1016\/j.prrv.2024.07.004_b0255","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jcf.2022.10.003","article-title":"Promise study group. Elexacaftor\/tezacaftor\/ivacaftor and gastrointestinal outcomes in cystic fibrosis: report of promise-GI","volume":"22","author":"Schwarzenberg","year":"2023","journal-title":"J Cyst Fibros."},{"key":"10.1016\/j.prrv.2024.07.004_b0260","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.877118","article-title":"Elexacaftor-tezacaftor-ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-score","volume":"13","author":"Mainz","year":"2022","journal-title":"Front Pharmacol"}],"container-title":["Paediatric Respiratory Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054224000769?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054224000769?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T09:05:35Z","timestamp":1747818335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526054224000769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":52,"alternative-id":["S1526054224000769"],"URL":"https:\/\/doi.org\/10.1016\/j.prrv.2024.07.004","relation":{},"ISSN":["1526-0542"],"issn-type":[{"value":"1526-0542","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of highly effective modulator therapy on gastrointestinal symptoms and features in people with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Paediatric Respiratory Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prrv.2024.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}